Amarin Says Off-Label Marketing Rules Flout 1st Amendment
Amarin Pharma Inc. sued the U.S. Food and Drug Administration on Thursday, arguing that the agency's curbs on drugmakers promoting drugs to doctors for unapproved uses amounts to a violation of...To view the full article, register now.
Already a subscriber? Click here to view full article